1. Home
  2. INMD vs DSGN Comparison

INMD vs DSGN Comparison

Compare INMD & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InMode Ltd.

INMD

InMode Ltd.

HOLD

Current Price

$13.97

Market Cap

842.0M

Sector

Health Care

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$11.06

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INMD
DSGN
Founded
2008
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
842.0M
819.6M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
INMD
DSGN
Price
$13.97
$11.06
Analyst Decision
Hold
Strong Buy
Analyst Count
5
4
Target Price
$17.33
$15.25
AVG Volume (30 Days)
716.6K
957.8K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.74
N/A
Revenue Next Year
$3.26
N/A
P/E Ratio
$10.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.72
$3.33
52 Week High
$16.74
$17.25

Technical Indicators

Market Signals
Indicator
INMD
DSGN
Relative Strength Index (RSI) 48.55 39.21
Support Level $13.27 $9.25
Resistance Level $14.70 $13.54
Average True Range (ATR) 0.30 1.39
MACD -0.02 -0.53
Stochastic Oscillator 57.54 15.47

Price Performance

Historical Comparison
INMD
DSGN

About INMD InMode Ltd.

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: